GLP1R and type 2 diabetes mellitus: For obese patients without (a very high risk for) CVD or T2DM, currently only GLP‐1 receptor agonist liraglutide (Saxenda) is reimbursed when a BMI ≥ 35 kg/m2 + CVD/OSAS/arthrosis or BMI ≥ 40 kg/m2 and at least 1 year Combined Lifestyle Program (GLI) is followed.